Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Emerging research supports the safety and efficacy of psychedelic-assisted therapy (PAT) in a controlled clinical environment for several treatment-resistant psychiatric disorders including depression, PTSD, substance use disorders, social anxiety, and obsessive-compulsive disorder.
“Emerging research supports the safety and efficacy of psychedelic-assisted therapy (PAT) when administered in a controlled clinical environment (1, 2) for several treatment-resistant psychiatric disorders including depression (3–5), post-traumatic stress disorder (PTSD) (6, 7), substance use disorders (8, 9), social anxiety (10), and obsessive-compulsive disorder (11).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [3]
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · see citing works
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167 · see citing works
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · see citing works
Defining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447 · see citing works
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347 · see citing works
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
López‐Giménez, J. F., & González‐Maeso, J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_478 · Cited by 311 · see citing works
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis
Goldberg, S. B., Pace, B. T., Nicholas, C. R. N., Raison, C. L., & Hutson, P. R. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112749 · Cited by 231 · see citing works
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.108 · Cited by 179 · see citing works
Perez, N., Langlest, F., Mallet, L., De Pieri, M., Sentissi, O., Thorens, G., Seragnoli, F., Zullino, D., Kirschner, M., Kaiser, S., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.07.011 · Cited by 88 · see citing works
More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression
Lyons, T., & Carhart-Harris, R. L. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01721 · Cited by 77 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The future of psychiatry: clinical practice, diagnosis, and treatment
Turner, S., Yadav, P., Morrin, H., & Bhat, A. (2025) · International Review of Psychiatry · doi:10.1080/09540261.2025.2594523 · Cited by 22 · see citing works
Świeczkowski, D., Kwaśny, A., Pruc, M., Gaca, Z., Szarpak, P. L., & Cubała, W. J. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116337 · Cited by 21 · see citing works
Psilocybin and Hallucinogenic Mushrooms
Fradet, M., Kelly, C. M., Donnelly, A. J., & Suppes, T. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009585330.004 · Cited by 12 · see citing works
Dominiak, M., Gędek, A., Modrzejewski, S., Permoda-Pachuta, A., & Antosik-Wójcińska, A. Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010253 · Cited by 7 · see citing works
Albert, A. E., & Back, A. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1529427 · Cited by 6 · see citing works
A systematic review of psychedelic use and its relationship with meaning and purpose in life
Rupiński, P., Drabek, W., & Holas, P. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00442 · Cited by 3 · see citing works
de Miranda, A. S., Toscano, E. C. D. B., Venna, V. R., Graeff, F. G., & Teixeira, A. L. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2460674 · Cited by 2 · see citing works
Koning, E., Gamberg, S., & Keshen, A. R. (2026) · Behavioral Sciences · doi:10.3390/bs16030376 · Cited by 1 · see citing works
Rosa, W. E., Napolitano, S., McAndrew, N., Jenkins, B., Lichtenthal, W. G., Applebaum, A. J., BREITBART, W. S., & Agrawal, M. (2025) · Psychedelic Medicine · doi:10.1177/28314425251363983
Koning, E., Richard, J., & Keshen, A. R. (2026) · International Journal of Eating Disorders · doi:10.1002/eat.70164
de Moura, M. V., Rocha, H. A. A., Lima, M. J. D. C., Medeiros, A. C. M., & Rosolen, I. C. (2026) · Revista JRG de Estudos Acadêmicos · doi:10.55892/jrg.v9i21.3741
- Authors
- Fang, Q., Chan, V. K. Y., Chan, S. S. M., Jiao, Y., Wang, J., & Li, X.
- Affiliations
- University of Hong Kong (HK)
- Chinese University of Hong Kong (HK)
- Laboratory of Data Discovery for Health (HK)
- Corresponding author
- Li, Xue
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 337
- Pages
- 115960
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W4398195443
- Cited by
- 9
- References
- 11
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- green
- hub.hku.hk
- Licence
- Locations
- Psychiatry Research (publishedVersion)
- PubMed (publishedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
- Funders
- University Grants Committee (R7007\u201322)
- University of Hong Kong
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- psilocybin, treatment-resistant depression, antidepressant efficacy, drug safety, psychedelic therapy
- MeSH terms
- Hallucinogens, Humans, Psilocybin, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
